|
H1 2020
|
Q2 2020
|
||||
$m
|
% change
|
$m
|
% change
|
|||
Actual
|
CER2
|
Actual
|
CER
|
|||
Total Revenue
|
12,629
|
12
|
14
|
6,275
|
8
|
11
|
Product Sales
|
12,359
|
11
|
13
|
6,048
|
6
|
9
|
Collaboration Revenue
|
270
|
n/m3
|
n/m
|
227
|
n/m
|
n/m
|
|
|
|
|
|
|
|
Reported4
EPS5
|
$1.17
|
n/m
|
n/m
|
$0.58
|
n/m
|
n/m
|
Core6
EPS
|
$2.01
|
24
|
26
|
$0.96
|
32
|
31
|
|
H1 2020
|
Q2 2020
|
||||
$m
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||
Tagrisso: Product
Sales
|
2,016
|
43
|
45
|
1,034
|
32
|
35
|
Imfinzi: Product
Sales
|
954
|
51
|
52
|
492
|
46
|
48
|
Lynparza: Product
Sales
|
816
|
57
|
60
|
419
|
48
|
52
|
Calquence: Product Sales
|
195
|
n/m
|
n/m
|
107
|
n/m
|
n/m
|
Enhertu: Collaboration
Revenue
|
36
|
n/m
|
n/m
|
22
|
n/m
|
n/m
|
|
H1 2020
|
Q2 2020
|
||||
$m
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||
Farxiga: Product
Sales
|
848
|
17
|
21
|
443
|
17
|
23
|
Brilinta: Product
Sales
|
845
|
15
|
17
|
437
|
12
|
16
|
Bydureon: Product
Sales
|
216
|
(24)
|
(23)
|
116
|
(18)
|
(17)
|
Lokelma: Product
Sales
|
28
|
n/m
|
n/m
|
17
|
n/m
|
n/m
|
Roxadustat: Collaboration Revenue
|
11
|
n/m
|
n/m
|
9
|
n/m
|
n/m
|
|
H1 2020
|
Q2 2020
|
||||
$m
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||
Symbicort: Product
Sales
|
1,442
|
23
|
26
|
653
|
12
|
15
|
Pulmicort: Product
Sales
|
477
|
(33)
|
(32)
|
97
|
(71)
|
(69)
|
Fasenra: Product
Sales
|
426
|
44
|
45
|
227
|
36
|
37
|
Regulatory
approvals
|
- Lynparza - ovarian cancer (1st line,
HRD+1) (PAOLA-1) (US)
- Lynparza - pancreatic cancer (1st line,
BRCAm2) (EU)
- Lynparza - prostate cancer (2nd line,
HRRm3) (US)
- Bevespi - COPD8 (CN)
- Breztri - COPD (US)
|
Regulatory
submission acceptances and/or submissions
|
- Enhertu - breast cancer (3rd line,
HER2+9) (EU)
- Enhertu - gastric cancer (3rd line,
HER2+) (JP)
- Brilinta/Brilique - stroke (THALES) (US,
EU)
|
Major
Phase III data readouts or other significant
developments
|
- Enhertu - breast cancer (3rd line,
HER2+): accelerated assessment (EU)
- Enhertu - gastric cancer (HER2+):
Orphan Drug Designation, Breakthrough Therapy Designation
(US)
- Calquence - CLL14: positive opinion (EU)
- selumetinib -
NF115: orphan drug designation
(JP)
- Farxiga - CKD16: primary, all secondary endpoints
met
- Brilinta - stroke (THALES): Priority
Review (US)
|
Timing
|
News
flow
|
H2 2020
|
- Tagrisso - adjuvant NSCLC
(EGFRm17): regulatory submission
- Imfinzi - unresectable18, Stage III NSCLC (PACIFIC-2): data
readout
- Imfinzi - ES-SCLC: regulatory decision
(EU, JP)
- Imfinzi +/- treme19 - liver cancer (1st line): data
readout, regulatory submission
- Lynparza - ovarian cancer (1st line)
(PAOLA-1): regulatory decision (EU, JP)
- Lynparza - ovarian cancer (3rd line,
BRCAm): regulatory submission
- Lynparza - breast cancer (BRCAm):
regulatory decision (CN)
- Lynparza - prostate cancer (2nd line):
regulatory decision (EU)
- Enhertu - breast cancer (3rd line,
HER2+): regulatory decision (EU)
- Enhertu - gastric cancer (3rd line,
HER2+): regulatory decision (JP)
- Calquence - CLL: regulatory decision
(EU)
- Forxiga - T2D CVOT: regulatory decision
(CN)
- Forxiga - HF CVOT: regulatory decision
(EU, JP)
- Farxiga - CKD: regulatory
submission
- Brilinta - stroke (THALES): regulatory
decision (US)
- Brilinta - stroke (THALES): regulatory
submission (CN)
- roxadustat -
anaemia in CKD: regulatory decision (US)
- Symbicort - mild asthma: regulatory
decision (CN)
- Symbicort - mild asthma: regulatory
submission (EU)
- Fasenra - nasal polyposis20: data readout
- PT010 - COPD:
regulatory decision (EU)
- tezepelumab -
severe asthma: data readout
- anifrolumab - lupus
(SLE21): regulatory submission
- AZD1222 -
SARS-CoV-2: data readout, regulatory submission
|
H1 2021
|
- Imfinzi - unresectable, Stage III NSCLC
(PACIFIC-2): regulatory submission
- Imfinzi - NSCLC (1st line) (PEARL):
data readout
- Imfinzi +/- treme - head & neck
cancer (1st line): data readout, regulatory submission
- Lynparza - pancreatic cancer (1st line,
BRCAm): regulatory decision (JP)
- Lynparza - prostate cancer (2nd line):
regulatory decision (JP)
- Lynparza - adjuvant breast cancer: data
readout
- Calquence - CLL: regulatory decision
(JP)
- Koselugo - NF1 regulatory decision
(EU)
- Forxiga - HF CVOT: regulatory decision
(CN)
- Brilique/Brilinta - CAD/T2D CVOT: regulatory
decision (EU, JP, CN)
- Brilique - stroke (THALES): regulatory
decision (EU)
- Fasenra - nasal polyposis: regulatory
submission
- tezepelumab -
severe asthma: regulatory submission
|
H2 2021
|
- Imfinzi - NSCLC (1st line) (PEARL):
regulatory submission
- Imfinzi - adjuvant bladder cancer: data
readout
- Imfinzi - liver cancer (locoregional):
data readout, regulatory submission
- Imfinzi - biliary tract cancer: data
readout
- Imfinzi +/- treme - NSCLC (1st line)
(POSEIDON): data readout (OS), regulatory submission
- Lynparza - adjuvant breast cancer:
regulatory submission
- Lynparza - prostate cancer (1st line,
castration-resistant): data readout, regulatory
submission
- Enhertu - breast cancer (3rd line,
HER2+) (Phase III): data readout
- Enhertu - breast cancer (2nd line,
HER2+): data readout, regulatory submission
- Enhertu - breast cancer (HER2
low22): data readout
- Calquence - CLL (2nd line) (ELEVATE
R/R): data readout, regulatory submission
- Farxiga - HF (HFpEF23): data readout, regulatory
submission
- PT027 - asthma:
data readout, regulatory submission
|
|
H1 2020
|
Q2 2020
|
||||||
$m
|
% of total
|
% change
|
$m
|
% of total
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||||
Oncology
|
5,324
|
42
|
28
|
31
|
2,806
|
45
|
25
|
28
|
BioPharmaceuticals
|
4,941
|
39
|
7
|
9
|
2,285
|
36
|
(1)
|
2
|
New CVRM
|
2,265
|
18
|
8
|
11
|
1,163
|
19
|
10
|
13
|
Respiratory & Immunology
|
2,676
|
21
|
5
|
7
|
1,122
|
18
|
(11)
|
(8)
|
Other
medicines
|
2,364
|
19
|
(7)
|
(4)
|
1,184
|
19
|
(6)
|
(2)
|
|
|
|
|
|
|
|
|
|
Total
|
12,629
|
100
|
12
|
14
|
6,275
|
100
|
8
|
11
|
Medicine
|
Therapy Area
|
H1 2020
|
Q2 2020
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
||||
Actual
|
CER
|
Actual
|
CER
|
|||||
Tagrisso
|
Oncology
|
2,016
|
16
|
43
|
45
|
1,034
|
32
|
35
|
Symbicort
|
Respiratory & Immunology
|
1,442
|
11
|
23
|
26
|
653
|
12
|
15
|
Imfinzi
|
Oncology
|
954
|
8
|
51
|
52
|
492
|
46
|
48
|
Lynparza
|
Oncology
|
951
|
8
|
64
|
66
|
554
|
62
|
65
|
Farxiga
|
CVRM
|
850
|
7
|
17
|
21
|
444
|
17
|
23
|
Brilinta
|
CVRM
|
845
|
7
|
15
|
17
|
437
|
12
|
16
|
Nexium
|
Other medicines
|
731
|
6
|
(5)
|
(3)
|
384
|
(4)
|
(1)
|
Crestor
|
CVRM
|
583
|
5
|
(10)
|
(7)
|
282
|
(9)
|
(6)
|
Zoladex
|
Oncology
|
484
|
4
|
22
|
27
|
257
|
28
|
34
|
Pulmicort
|
Respiratory & Immunology
|
477
|
4
|
(33)
|
(32)
|
97
|
(71)
|
(69)
|
|
|
|
|
|
|
|
|
|
Total
|
|
9,333
|
74
|
20
|
22
|
4,634
|
14
|
17
|
|
H1 2020
|
Q2 2020
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
||||
Lynparza: regulatory milestone
revenue
|
135
|
50
|
n/m
|
n/m
|
135
|
n/m
|
n/m
|
Enhertu: profit
share
|
36
|
13
|
n/m
|
n/m
|
22
|
n/m
|
n/m
|
Roxadustat: profit share
|
11
|
4
|
n/m
|
n/m
|
9
|
n/m
|
n/m
|
Other Collaboration Revenue
|
88
|
33
|
24
|
25
|
61
|
36
|
36
|
|
|
|
|
|
|
|
|
Total
|
270
|
100
|
n/m
|
n/m
|
227
|
n/m
|
n/m
|
Product Sales: therapy area
|
Medicine
|
H1 2020
|
|||
$m
|
% of total Product Sales
|
% change
|
|||
Actual
|
CER
|
||||
Oncology
|
Tagrisso
|
2,016
|
16
|
43
|
45
|
Imfinzi
|
954
|
8
|
51
|
52
|
|
Lynparza
|
816
|
7
|
57
|
60
|
|
Calquence
|
195
|
2
|
n/m
|
n/m
|
|
Koselugo
|
7
|
-
|
n/m
|
n/m
|
|
Zoladex
|
442
|
4
|
13
|
18
|
|
Faslodex
|
312
|
3
|
(40)
|
(38)
|
|
Iressa
|
147
|
1
|
(42)
|
(40)
|
|
Arimidex
|
107
|
1
|
(3)
|
-
|
|
Casodex
|
89
|
1
|
(15)
|
(13)
|
|
Others
|
26
|
-
|
(50)
|
(47)
|
|
Total Oncology
|
5,111
|
41
|
26
|
28
|
|
BioPharmaceuticals: CVRM
|
Farxiga
|
848
|
7
|
17
|
21
|
Brilinta
|
845
|
7
|
15
|
17
|
|
Onglyza
|
256
|
2
|
(5)
|
(3)
|
|
Bydureon
|
216
|
2
|
(24)
|
(23)
|
|
Byetta
|
35
|
-
|
(36)
|
(35)
|
|
Other diabetes
|
23
|
-
|
3
|
6
|
|
Lokelma
|
28
|
-
|
n/m
|
n/m
|
|
Crestor
|
582
|
5
|
(10)
|
(8)
|
|
Seloken/Toprol-XL
|
395
|
3
|
-
|
6
|
|
Atacand
|
126
|
1
|
19
|
25
|
|
Others
|
106
|
1
|
(20)
|
(18)
|
|
BioPharmaceuticals:
total CVRM
|
3,460
|
28
|
3
|
6
|
|
BioPharmaceuticals: Respiratory & Immunology
|
Symbicort
|
1,442
|
12
|
23
|
26
|
Pulmicort
|
477
|
4
|
(33)
|
(32)
|
|
Fasenra
|
426
|
3
|
44
|
45
|
|
Daliresp/Daxas
|
106
|
1
|
1
|
2
|
|
Bevespi
|
22
|
-
|
10
|
10
|
|
Breztri
|
11
|
-
|
n/m
|
n/m
|
|
Others
|
184
|
1
|
(20)
|
(18)
|
|
BioPharmaceuticals: total Respiratory & Immunology
|
2,668
|
22
|
5
|
7
|
|
Other medicines
|
Nexium
|
714
|
6
|
(5)
|
(3)
|
Synagis
|
176
|
1
|
18
|
18
|
|
Losec/Prilosec
|
99
|
1
|
(32)
|
(30)
|
|
Seroquel XR/IR
|
63
|
1
|
(9)
|
(8)
|
|
Others
|
68
|
1
|
(32)
|
(31)
|
|
Total other medicines
|
1,120
|
9
|
(8)
|
(6)
|
|
|
Total Product Sales
|
12,359
|
100
|
11
|
13
|
|
|||||
Total Collaboration Revenue
|
270
|
|
n/m
|
n/m
|
|
|
|||||
Total Revenue
|
12,629
|
|
12
|
14
|
Product Sales: therapy area
|
Medicine
|
Q2 2020
|
|||
$m
|
% of total Product Sales
|
% change
|
|||
Actual
|
CER
|
||||
Oncology
|
Tagrisso
|
1,034
|
17
|
32
|
35
|
Imfinzi
|
492
|
8
|
46
|
48
|
|
Lynparza
|
419
|
7
|
48
|
52
|
|
Calquence
|
107
|
2
|
n/m
|
n/m
|
|
Koselugo
|
7
|
-
|
n/m
|
n/m
|
|
Zoladex
|
217
|
4
|
10
|
17
|
|
Faslodex
|
146
|
2
|
(45)
|
(43)
|
|
Iressa
|
70
|
1
|
(41)
|
(38)
|
|
Arimidex
|
58
|
1
|
(4)
|
-
|
|
Casodex
|
47
|
1
|
(17)
|
(15)
|
|
Others
|
12
|
-
|
(59)
|
(55)
|
|
Total Oncology
|
2,609
|
43
|
20
|
24
|
|
BioPharmaceuticals: CVRM
|
Farxiga
|
443
|
7
|
17
|
23
|
Brilinta
|
437
|
7
|
12
|
16
|
|
Onglyza
|
115
|
2
|
(1)
|
3
|
|
Bydureon
|
116
|
2
|
(18)
|
(17)
|
|
Byetta
|
15
|
-
|
(42)
|
(41)
|
|
Other diabetes
|
10
|
-
|
(9)
|
(5)
|
|
Lokelma
|
17
|
-
|
n/m
|
n/m
|
|
Crestor
|
281
|
5
|
(10)
|
(6)
|
|
Seloken/Toprol-XL
|
218
|
4
|
29
|
38
|
|
Atacand
|
59
|
1
|
6
|
14
|
|
Others
|
48
|
1
|
(23)
|
(20)
|
|
BioPharmaceuticals:
total CVRM
|
1,759
|
29
|
6
|
10
|
|
BioPharmaceuticals: Respiratory & Immunology
|
Symbicort
|
653
|
11
|
12
|
15
|
Pulmicort
|
97
|
2
|
(71)
|
(69)
|
|
Fasenra
|
227
|
4
|
36
|
37
|
|
Daliresp/Daxas
|
53
|
1
|
(7)
|
(7)
|
|
Bevespi
|
10
|
-
|
(1)
|
(3)
|
|
Breztri
|
7
|
-
|
n/m
|
n/m
|
|
Others
|
70
|
1
|
(30)
|
(28)
|
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,117
|
18
|
(11)
|
(8)
|
|
Other medicines
|
Nexium
|
377
|
6
|
(4)
|
(1)
|
Synagis
|
90
|
1
|
(5)
|
(5)
|
|
Losec/Prilosec
|
45
|
1
|
(34)
|
(31)
|
|
Seroquel XR/IR
|
27
|
-
|
(16)
|
(14)
|
|
Others
|
24
|
-
|
(53)
|
(52)
|
|
Total other medicines
|
563
|
9
|
(12)
|
(10)
|
|
|
Total Product Sales
|
6,048
|
100
|
6
|
9
|
|
|||||
Total Collaboration Revenue
|
227
|
|
n/m
|
n/m
|
|
|
|||||
Total Revenue
|
6,275
|
|
8
|
11
|
|
H1 2020
|
Q2 2020
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
||||
Emerging Markets
|
4,329
|
34
|
9
|
15
|
2,056
|
6
|
13
|
China
|
2,659
|
21
|
10
|
14
|
1,243
|
7
|
12
|
Ex-China
|
1,671
|
13
|
8
|
15
|
813
|
4
|
15
|
|
|
|
|
|
|
|
|
US
|
4,177
|
33
|
13
|
13
|
2,085
|
10
|
10
|
|
|
|
|
|
|
|
|
Europe
|
2,447
|
19
|
17
|
20
|
1,244
|
12
|
15
|
|
|
|
|
|
|
|
|
Established RoW
|
1,676
|
13
|
7
|
7
|
890
|
2
|
3
|
Japan
|
1,232
|
10
|
3
|
2
|
679
|
(2)
|
(3)
|
Canada
|
298
|
2
|
33
|
35
|
143
|
28
|
35
|
Other Established
RoW
|
145
|
1
|
2
|
10
|
68
|
6
|
17
|
|
|
|
|
|
|
|
|
Total
|
12,629
|
100
|
12
|
14
|
6,275
|
8
|
11
|
|
H1 2020
|
Q2 2020
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
||||
Oncology
|
1,461
|
34
|
39
|
46
|
750
|
34
|
43
|
BioPharmaceuticals
|
1,480
|
34
|
-
|
5
|
608
|
(15)
|
(9)
|
New CVRM
|
719
|
17
|
38
|
46
|
387
|
37
|
48
|
Respiratory &
Immunology
|
761
|
18
|
(20)
|
(17)
|
221
|
(49)
|
(45)
|
Other medicines
|
1,389
|
32
|
(3)
|
2
|
697
|
4
|
11
|
|
|
|
|
|
|
|
|
Total
|
4,329
|
100
|
9
|
15
|
2,056
|
6
|
13
|
|
H1 2020
|
Q2 2020
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
||||
Tagrisso
|
595
|
14
|
81
|
89
|
315
|
65
|
74
|
Forxiga
|
306
|
7
|
49
|
59
|
165
|
49
|
62
|
Brilinta
|
291
|
7
|
34
|
40
|
156
|
30
|
39
|
Lynparza26
|
120
|
3
|
n/m
|
n/m
|
64
|
95
|
n/m
|
|
H1 2020
|
Q2 2020
|
||||
$m
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||
Ex-China Asia Pacific
|
597
|
5
|
7
|
286
|
(1)
|
2
|
Middle East and Africa
|
530
|
10
|
12
|
266
|
9
|
12
|
Ex-Brazil Latin America
|
206
|
(2)
|
14
|
98
|
(10)
|
11
|
Russia
|
175
|
57
|
67
|
91
|
45
|
68
|
Brazil
|
161
|
(6)
|
16
|
72
|
(6)
|
28
|
|
H1 2020
|
H1 2019
|
% change
|
|
$m
|
$m
|
Actual
|
CER
|
|
Total Revenue
|
12,629
|
11,314
|
12
|
14
|
Product Sales
|
12,359
|
11,183
|
11
|
13
|
Collaboration Revenue
|
270
|
131
|
n/m
|
n/m
|
|
|
|
|
|
Cost of Sales
|
(2,404)
|
(2,192)
|
10
|
15
|
|
|
|
|
|
Gross Profit
|
10,225
|
9,122
|
12
|
14
|
Gross Profit Margin
|
80.5%
|
80.4%
|
-
|
-
|
|
|
|
|
|
Distribution Expense
|
(191)
|
(159)
|
20
|
25
|
% Total Revenue
|
1.5%
|
1.4%
|
-
|
-
|
R&D Expense
|
(2,777)
|
(2,622)
|
6
|
7
|
% Total Revenue
|
22.0%
|
23.2%
|
+1
|
+1
|
SG&A Expense
|
(5,354)
|
(5,457)
|
(2)
|
-
|
% Total Revenue
|
42.4%
|
48.2%
|
+6
|
+6
|
|
|
|
|
|
Other Operating Income & Expense
|
601
|
706
|
(15)
|
(13)
|
% Total Revenue
|
4.8%
|
6.2%
|
-1
|
-1
|
|
|
|
|
|
Operating Profit
|
2,504
|
1,590
|
57
|
58
|
Operating Profit Margin
|
19.8%
|
14.1%
|
+6
|
+6
|
|
|
|
|
|
Net Finance Expense
|
(588)
|
(632)
|
(7)
|
(7)
|
Joint Ventures and Associates
|
(20)
|
(59)
|
(66)
|
(63)
|
|
|
|
|
|
Profit Before Tax
|
1,896
|
899
|
n/m
|
n/m
|
|
|
|
|
|
Taxation
|
(408)
|
(229)
|
78
|
76
|
Tax Rate
|
22%
|
25%
|
|
|
|
|
|
|
|
Profit After Tax
|
1,488
|
670
|
n/m
|
n/m
|
|
|
|
|
|
EPS
|
$1.17
|
$0.56
|
n/m
|
n/m
|
|
Q2 2020
|
Q2 2019
|
% change
|
|
$m
|
$m
|
Actual
|
CER
|
|
Total Revenue
|
6,275
|
5,823
|
8
|
11
|
Product Sales
|
6,048
|
5,718
|
6
|
9
|
Collaboration Revenue
|
227
|
105
|
n/m
|
n/m
|
|
|
|
|
|
Cost of Sales
|
(984)
|
(1,063)
|
(7)
|
3
|
|
|
|
|
|
Gross Profit
|
5,291
|
4,760
|
11
|
13
|
Gross Profit Margin
|
83.7%
|
81.4%
|
+2
|
+1
|
|
|
|
|
|
Distribution Expense
|
(104)
|
(81)
|
29
|
37
|
% Total Revenue
|
1.7%
|
1.4%
|
-
|
-
|
R&D Expense
|
(1,389)
|
(1,356)
|
2
|
4
|
% Total Revenue
|
22.1%
|
23.3%
|
+1
|
+1
|
SG&A Expense
|
(2,635)
|
(2,943)
|
(10)
|
(8)
|
% Total Revenue
|
42.0%
|
50.6%
|
+9
|
+8
|
|
|
|
|
|
Other Operating Income & Expense
|
121
|
113
|
7
|
19
|
% Total Revenue
|
1.9%
|
2.0%
|
-
|
-
|
|
|
|
|
|
Operating Profit
|
1,284
|
493
|
n/m
|
n/m
|
Operating Profit Margin
|
20.5%
|
8.5%
|
+12
|
+11
|
|
|
|
|
|
Net Finance Expense
|
(307)
|
(320)
|
(4)
|
(5)
|
Joint Ventures and Associates
|
(16)
|
(32)
|
(50)
|
(45)
|
|
|
|
|
|
Profit Before Tax
|
961
|
141
|
n/m
|
n/m
|
|
|
|
|
|
Taxation
|
(223)
|
(34)
|
n/m
|
n/m
|
Tax Rate
|
23%
|
24%
|
|
|
|
|
|
|
|
Profit After Tax
|
738
|
107
|
n/m
|
n/m
|
|
|
|
|
|
EPS
|
$0.58
|
$0.09
|
n/m
|
n/m
|
|
H1 2020
|
H1 2019
|
% change
|
|
$m
|
$m
|
Actual
|
CER
|
|
Reported Profit Before Tax
|
1,896
|
899
|
n/m
|
n/m
|
Net Finance Expense
|
588
|
632
|
(7)
|
(7)
|
Joint Ventures and Associates
|
20
|
59
|
(66)
|
(63)
|
Depreciation, Amortisation and Impairment
|
1,551
|
1,403
|
11
|
12
|
|
|
|
|
|
EBITDA
|
4,055
|
2,993
|
35
|
37
|
|
Q2 2020
|
Q2 2019
|
% change
|
|
$m
|
$m
|
Actual
|
CER
|
|
Reported Profit Before Tax
|
961
|
141
|
n/m
|
n/m
|
Net Finance Expense
|
307
|
320
|
(4)
|
(5)
|
Joint Ventures and Associates
|
16
|
32
|
(50)
|
(45)
|
Depreciation, Amortisation and Impairment
|
710
|
727
|
(2)
|
-
|
|
|
|
|
|
EBITDA
|
1,994
|
1,220
|
63
|
63
|
H1 2020
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Diabetes Alliance
|
Other
|
Core
|
Core
% change
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross Profit
|
10,225
|
35
|
33
|
-
|
5
|
10,298
|
12
|
13
|
Gross Profit Margin
|
80.5%
|
|
|
|
|
81.1%
|
-
|
-1
|
|
|
|
|
|
|
|
|
|
Distribution Expense
|
(191)
|
-
|
-
|
-
|
-
|
(191)
|
20
|
25
|
R&D Expense
|
(2,777)
|
16
|
49
|
-
|
-
|
(2,712)
|
8
|
9
|
SG&A Expense
|
(5,354)
|
45
|
809
|
152
|
(5)
|
(4,353)
|
2
|
5
|
Total Operating Expenses
|
(8,322)
|
61
|
858
|
152
|
(5)
|
(7,256)
|
5
|
7
|
|
|
|
|
|
|
|
|
|
Other Operating Income & Expense
|
601
|
2
|
1
|
-
|
-
|
604
|
(15)
|
(13)
|
|
|
|
|
|
|
|
|
|
Operating Profit
|
2,504
|
98
|
892
|
152
|
-
|
3,646
|
21
|
23
|
Operating Profit Margin
|
19.8%
|
|
|
|
|
28.9%
|
+2
|
+2
|
|
|
|
|
|
|
|
|
|
Net Finance Expense
|
(588)
|
-
|
-
|
115
|
104
|
(369)
|
(5)
|
(7)
|
Taxation
|
(408)
|
(20)
|
(183)
|
(60)
|
(1)
|
(672)
|
26
|
28
|
|
|
|
|
|
|
|
|
|
EPS
|
$1.17
|
$0.06
|
$0.54
|
$0.16
|
$0.08
|
$2.01
|
24
|
26
|
Q2 2020
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Diabetes Alliance
|
Other
|
Core
|
Core % change
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross Profit
|
5,291
|
16
|
16
|
-
|
-
|
5,323
|
11
|
12
|
Gross Profit Margin
|
83.7%
|
|
|
|
|
84.3%
|
+2
|
+1
|
|
|
|
|
|
|
|
|
|
Distribution Expense
|
(104)
|
-
|
-
|
-
|
-
|
(104)
|
29
|
37
|
R&D Expense
|
(1,389)
|
5
|
7
|
-
|
1
|
(1,376)
|
8
|
9
|
SG&A Expense
|
(2,635)
|
20
|
360
|
85
|
(6)
|
(2,176)
|
(1)
|
3
|
Total Operating Expenses
|
(4,128)
|
25
|
367
|
85
|
(5)
|
(3,656)
|
3
|
6
|
|
|
|
|
|
|
|
|
|
Other Operating Income & Expense
|
121
|
4
|
-
|
-
|
-
|
125
|
9
|
21
|
|
|
|
|
|
|
|
|
|
Operating Profit
|
1,284
|
45
|
383
|
85
|
(5)
|
1,792
|
32
|
31
|
Operating Profit Margin
|
20.5%
|
|
|
|
|
28.6%
|
+5
|
+4
|
|
|
|
|
|
|
|
|
|
Net Finance Expense
|
(307)
|
-
|
-
|
58
|
49
|
(200)
|
1
|
(3)
|
Taxation
|
(223)
|
(9)
|
(76)
|
(29)
|
(1)
|
(338)
|
68
|
68
|
|
|
|
|
|
|
|
|
|
EPS
|
$0.58
|
$0.03
|
$0.23
|
$0.09
|
$0.03
|
$0.96
|
32
|
31
|
|
H1 2020
|
H1 2019
|
Change
|
$m
|
$m
|
$m
|
|
Reported Operating Profit
|
2,504
|
1,590
|
914
|
Depreciation, Amortisation and Impairment
|
1,551
|
1,403
|
148
|
|
|
|
|
Increase in Working Capital and Short-Term Provisions
|
(780)
|
(634)
|
(146)
|
Gains on Disposal of Intangible Assets
|
(411)
|
(590)
|
179
|
Non-Cash and Other Movements
|
(555)
|
(177)
|
(378)
|
Interest Paid
|
(338)
|
(378)
|
40
|
Taxation Paid
|
(792)
|
(723)
|
(69)
|
|
|
|
|
Net Cash Inflow from Operating Activities
|
1,179
|
491
|
688
|
|
|
|
|
Net Cash Inflow/(Outflow) Before Financing Activities
|
1,336
|
(298)
|
1,634
|
|
|
|
|
Net Cash (Outflow)/Inflow from Financing Activities
|
(1,236)
|
941
|
(2,177)
|
|
At 30 Jun 2020
|
At 31 Dec 2019
|
At 30 Jun 2019
|
$m
|
$m
|
$m
|
|
Cash
and Cash Equivalents
|
5,673
|
5,369
|
5,428
|
Other
Investments
|
442
|
911
|
875
|
|
|
|
|
Cash and Investments
|
6,115
|
6,280
|
6,303
|
|
|
|
|
Overdrafts
and Short-Term Borrowings
|
(1,799)
|
(225)
|
(629)
|
Lease
Liabilities
|
(639)
|
(675)
|
(720)
|
Current
Instalments of Loans
|
(2,159)
|
(1,597)
|
(1,000)
|
Non-Current
Instalments of Loans
|
(15,150)
|
(15,730)
|
(17,355)
|
|
|
|
|
Interest-Bearing Loans and Borrowings
(Gross Debt)
|
(19,747)
|
(18,227)
|
(19,704)
|
|
|
|
|
Net
Derivatives
|
(18)
|
43
|
321
|
Net Debt
|
(13,650)
|
(11,904)
|
(13,080)
|
|
Average Exchange
Rates versus USD
|
|
Annual Impact of 5% Strengthening in Exchange Rate versus USD
($m)30
|
|||
Currency
|
Primary Relevance
|
FY 201931
|
H1 202032
|
% change
|
Product Sales
|
Core Operating Profit
|
CNY
|
Product
Sales
|
6.92
|
6.88
|
-
|
288
|
190
|
EUR
|
Product
Sales
|
0.89
|
0.93
|
(4)
|
171
|
68
|
JPY
|
Product
Sales
|
108.98
|
105.74
|
3
|
139
|
98
|
Other33
|
|
|
|
|
231
|
123
|
|
|
|
|
|
|
|
GBP
|
Operating
Expense
|
0.78
|
0.81
|
(4)
|
27
|
(93)
|
SEK
|
Operating
Expense
|
9.46
|
9.45
|
-
|
5
|
(51)
|
New
molecular entities and major lifecycle events for medicines in
Phase III trials or under regulatory review
|
17
|
Oncology
- Tagrisso - NSCLC
- Imfinzi - multiple cancers
-
Lynparza - multiple
cancers
- Enhertu - multiple cancers
- capivasertib -
breast cancer
- Calquence - blood cancers
- tremelimumab -
multiple cancers
CVRM
- Farxiga - multiple
indications
- roxadustat -
anaemia in CKD
Respiratory & Immunology
- Fasenra - multiple
indications
- PT010 -
COPD
- PT027 -
asthma
- tezepelumab -
severe asthma
- nirsevimab -
respiratory syncytial virus
- anifrolumab - lupus
(SLE)
- brazikumab -
inflammatory bowel disease43
|
Total
projects
in
clinical pipeline
|
142
|
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
NeoADAURA
|
Neo-adjuvant
EGFRm
NSCLC
|
Placebo
or Tagrisso
|
FPCD39
Q2
2020
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
ADAURA
|
Adjuvant
EGFRm NSCLC
|
Placebo
or Tagrisso
|
FPCD
Q4
2015
LPCD40
Q1
2019
|
Trial
unblinded early due to overwhelming efficacy
|
Phase
III
LAURA
|
Locally
advanced, unresectable EGFRm NSCLC
|
Placebo
or Tagrisso
|
FPCD
Q4
2018
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
FLAURA2
|
1st-line
EGFRm NSCLC
|
Tagrisso or Tagrisso
+ platinum-based chemotherapy doublet
|
FPCD
Q4
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
MERMAID-1
|
Stage
II-III
resected
NSCLC
|
SoC
chemotherapy +/- Imfinzi
|
-
First
data anticipated
2021+
|
Initiating
|
Phase
III
AEGEAN
|
Neo-adjuvant
(before surgery) NSCLC
|
SoC
chemotherapy +/- Imfinzi,
followed
by
surgery,
followed by placebo or Imfinzi
|
FPCD
Q1
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
ADJUVANT
BR.3142
|
Stage
Ib-IIIa NSCLC
|
Placebo or
Imfinzi
|
FPCD
Q1
2015
LPCD
Q1
2020
First
data anticipated
2021+
|
Recruitment
completed
|
Phase
III
PACIFIC-2
|
Stage
III unresected locally advanced NSCLC
(concurrent
CRT)
|
Placebo or
Imfinzi
|
FPCD
Q2
2018
LPCD
Q3
2019
First
data anticipated
H2
2020
|
Recruitment
completed
|
Phase
III
ADRIATIC
|
Limited-
stage
SCLC
|
Concurrent
CRT,
followed
by
placebo
or
Imfinzi or Imfinzi +
treme
|
FPCD
Q4
2018
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
PEARL
|
Stage
IV, 1st-line NSCLC
|
SoC
chemotherapy or Imfinzi
|
FPCD
Q1
2017
LPCD
Q1
2019
First
data anticipated
H1
2021
|
Recruitment
completed
|
Phase
III
POSEIDON
|
Stage
IV, 1st-line NSCLC
|
SoC
chemotherapy or SoC +
Imfinzi or SoC +
Imfinzi +
treme
|
FPCD
Q2
2017
LPCD
Q4
2018
OS data
anticipated
H2
2021
|
PFS43
primary endpoint met
|
Phase
III
CASPIAN
|
ES-SCLC
|
SoC
chemotherapy or SoC +
Imfinzi or SoC +
Imfinzi +
treme
|
FPCD
Q1
2017
LPCD
Q2
2018
|
OS
primary endpoint met for Imfinzi monotherapy arm
OS
primary endpoint not met for Imfinzi + treme
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
POTOMAC
|
Non-muscle
invasive bladder cancer
|
SoC
BCG44 or SoC BCG + Imfinzi
|
FPCD
Q4
2018
First
data
anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
NIAGARA
|
Muscle-invasive
bladder cancer
|
Neo-adjuvant
cisplatin and gemcitabine SoC chemotherapy or SoC + Imfinzi, followed by adjuvant placebo
or Imfinzi
|
FPCD
Q4
2018
First
data
anticipated
H2
2021
|
Recruitment
ongoing
|
Phase
III
EMERALD-1
|
Locoregional
HCC45
|
TACE46
followed by placebo or TACE + Imfinzi, followed by Imfinzi +
bevacizumab
or
TACE +
Imfinzi
followed
by Imfinzi
|
FPCD
Q1
2019
First
data
anticipated
H2
2021
|
Recruitment
ongoing
|
Phase
III
EMERALD-2
|
Locoregional
HCC at high risk of recurrence after surgery or radiofrequency
ablation
|
Adjuvant
Imfinzi or Imfinzi + bevacizumab
|
FPCD
Q2
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
CALLA
|
Locally
advanced cervical cancer
|
CRT or
CRT + Imfinzi, followed by
placebo or Imfinzi
|
FPCD
Q1
2019
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
NILE
|
Stage
IV, 1st-line cisplatin chemotherapy- eligible bladder
cancer
|
SoC
chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
|
FPCD
Q4
2018
First
data anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
KESTREL
|
Stage
IV, 1st-line HNSCC47
|
SoC or
Imfinzi or Imfinzi + treme
|
FPCD
Q4
2015
LPCD
Q1
2017
First
data
anticipated
H1
2021
|
Recruitment
completed
|
Phase
III
HIMALAYA
|
Stage
IV, 1st-line unresectable HCC
|
Sorafenib or
Imfinzi or Imfinzi + treme
|
FPCD
Q4
2017
LPCD
Q4
2019
First
data
anticipated
H2
2020
|
Recruitment
completed
Orphan
Drug Designation (US)48
|
Phase
III
TOPAZ-1
|
Stage
IV, 1st-line biliary-tract cancer
|
Gemcitabine
and cisplatin SoC chemotherapy or SoC + Imfinzi
|
FPCD
Q2
2019
First
data anticipated
H2
2021
|
Recruitment
ongoing
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
III
OlympiA
|
Adjuvant
BRCAm breast cancer
|
SoC
placebo or Lynparza
|
FPCD
Q2
2014
LPCD
Q2
2019
First
data anticipated
H1
2021
|
Recruitment
completed
|
Phase
III
PROfound
|
Metastatic
castration-resistant 2nd-line+ HRRm
prostate
cancer
|
SoC
(abiraterone or enzalutamide) or Lynparza
|
FPCD
Q2
2017
LPCD
Q4
2018
|
Primary
endpoint met
Priority
Review (US)
|
Phase
III
PAOLA-149
|
Advanced
1st-line
ovarian
cancer
|
Bevacizumab
maintenance or
bevacizumab
+
Lynparza maintenance
|
FPCD
Q2
2015
LPCD
Q2
2018
|
Primary
endpoint met
Priority
Review (US)
|
Phase
II/III
GY005
|
Recurrent
platinum-resistant/refractory ovarian cancer
|
SoC
chemotherapy or cediranib or cediranib + Lynparza
|
FPCD
Q2
2016
(Phase
II)
FPCD
Q1
2019
(Phase
III)
First
data
anticipated
2021+
|
Recruitment
ongoing
(Phase
III component)
|
Phase
III
DuO-O
|
Advanced
1st-line
ovarian
cancer
|
Chemotherapy
+
bevacizumab
or
chemotherapy
+
bevacizumab
+
Imfinzi +/-
Lynparza maintenance
|
FPCD
Q1 2019
First
data
anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
DuO-E
|
Advanced
1st-line
endometrial
cancer
|
Chemotherapy
or
chemotherapy
+
Imfinzi + Imfinzi
maintenance or
chemotherapy
+
Imfinzi followed by Imfinzi + Lynparza maintenance
|
FPCD
Q2 2020
First
data
anticipated
2021+
|
Recruitment
ongoing
|
Phase
III
PROpel
|
Stage
IV, advanced, castration-resistant prostate cancer
|
Abiraterone
or
abiraterone
+
Lynparza
|
FPCD
Q4
2018
First
data
anticipated
H2
2021
|
Recruitment
ongoing
|
Phase
III
LYNK-003
|
Stage
IV, 1st-line colorectal cancer
|
Bevacizumab
+ 5-FU maintenance or bevacizumab + Lynparza maintenance or Lynparza maintenance
|
First
data
anticipated
2021+
|
Initiating
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Phase
II
DESTINY-Breast01
|
Stage
IV, HER2+50 breast cancer post trastuzumab
emtansine
|
Enhertu
(single
arm)
|
FPCD
Q4
2017
LPCD
Q4
2018
|
Primary
objective met
Breakthrough
Therapy Designation (US)
Approval
(JP), Accelerated Approval (US)
|
Phase
III
DESTINY-Breast02
|
Stage
IV, HER2+ breast cancer post trastuzumab emtansine
|
SoC
chemotherapy or Enhertu
|
FPCD
Q4
2018
First
data anticipated
H2
2021
|
Recruitment ongoing
|
Phase
III
DESTINY-Breast03
|
Stage
IV, HER2+ breast cancer
|
Trastuzumab
emtansine or Enhertu
|
FPCD
Q4
2018
First
data anticipated
H2
2021
|
Recruitment ongoing
|
Phase
III
DESTINY-Breast04
|
Stage
IV, HER2-low
|
SoC
chemotherapy or Enhertu
|
FPCD
Q4
2018
First
data anticipated
H2
2021
|
Recruitment ongoing
|
Phase
II
DESTINY-Gastric01
|
Stage
IV, HER2+ gastric cancer
|
SoC
chemotherapy or Enhertu
|
FPCD
Q4
2017
LPCD
Q2
2019
|
Primary
endpoint met
US
Breakthrough Therapy Designation
|
Phase
II
DPT02
|
HER2-expressing
tumours
|
Enhertu
|
-
|
Initiating
|
Trial
|
Population
|
Design
|
Primary endpoint(s)
|
Timeline
|
Status
|
Farxiga
|
|
||||
Phase
III
DAPA-HF
|
c.4,500
patients with HF with reduced ejection fraction, with and without
T2D
|
Arm 1:
Farxiga 10mg or 5mg
QD51 + SoC
Arm 2:
placebo + SoC
|
Time to
first occurrence of CV death or hospitalisation due to HF or an
urgent HF visit
|
FPCD
Q1
2017
LPCD
Q4
2018
|
Primary
endpoint met
Fast
Track designation (US)
|
Phase
III
DELIVER
|
c.4,700
patients with HF and preserved ejection fraction, with and without
T2D
|
Arm 1:
Farxiga 10mg
QD
Arm 2:
placebo
|
Time to
first occurrence of CV death or worsening HF
|
FPCD
Q4
2018
First
data anticipatedH2 2021
|
Recruitment
ongoing
Fast
Track designation (US)
|
Phase
III
DAPA-CKD
|
c.4,000
patients with CKD, with and without T2D
|
Arm 1:
Farxiga 10mg or 5mg
QD
Arm 2:
placebo
|
Time to
first occurrence of ≥ 50% sustained decline in eGFR or
reaching ESRD or CV death or renal death
|
FPCD
Q1
2017
LPCD
Q1
2020
|
Trial
stopped early based on recommendation from an IDMC
Primary
endpoint and secondary endpoints met
Fast
Track designation (US)
|
Brilinta
|
|
||||
Phase
III THEMIS
|
c.19,000
patients with T2D and CAD without a history of MI or
stroke
|
Arm 1:
Brilinta 60mg
BID52
Arm 2:
placebo BID on a background of aspirin if not
contra-indicated53 or not tolerated
|
Composite
of CV death, non-fatal MI and non-fatal stroke
|
FPCD
Q1
2014
LPCD
Q2
2016
|
Primary
endpoint met
|
Phase
III
THALES
|
c.11,000
patients with acute ischaemic stroke or transient ischaemic
attack
|
Arm 1:
Brilinta 90mg
BID
Arm 2:
placebo BID on a background of aspirin if not contra-indicated or
not tolerated
|
Prevention
of the composite of subsequent stroke and death at 30
days
|
FPCD
Q1
2018
LPCD
Q4
2019
|
Primary
endpoint met
Fast
Track
designation
(US)
|
Trial
|
Population
|
Design
|
Primary endpoint(s)
|
Timeline
|
Status
|
Phase
III OSTRO
|
Patients
(aged 18-75 years) with severe bilateral nasal polyposis;
symptomatic, despite SoC
|
Nasal-polyposis
burden and reported nasal blockage
|
FPCD
Q1
2018
LPCD
Q2
2019
Data
anticipated
H2
2020
|
Recruitment
completed
|
|
Phase
III RESOLUTE
|
Patients
with moderate to very severe COPD with a history of frequent COPD
exacerbations and elevated peripheral blood
eosinophils
|
Placebo
or Fasenra 100mg Q8W
SC
|
Annualised
rate of moderate or severe COPD exacerbations
|
FPCD
Q4
2019
Data
anticipated 2021+
|
Recruitment
ongoing
|
Phase
III
MANDARA
|
Eosinophilic
granulomatosis with polyangiitis56
|
Fasenra 30mg or
mepolizumab
3x100mg Q4W57
|
Proportion
of patients who achieve remission, defined as a score58 =0 and an OCS dose ≤4 mg/day at
weeks 36 and 48
|
FPCD
Q4
2019
Data
anticipated
2021+
|
Recruitment
ongoing
Orphan
Drug Designation (US)
|
Phase
III
NATRON
|
HES59
|
Placebo
or Fasenra 30mg Q4W
SC
|
Time to
HES worsening flare or any cytotoxic and/or immuno-suppressive
therapy increase or hospitalisation
|
FPCD
Q3
2020
Data
anticipated 2021+
|
Recruitment
ongoing
Orphan
Drug Designation (US)
|
Phase
III
MESSINA
|
Eosinophilic
oesophagitis60
|
Placebo
or Fasenra 30mg Q4W
SC
|
Proportion
of patients with a histologic response
Changes
from baseline in dysphagia PRO61
|
Data
anticipated 2021+
|
Initiating
Orphan
Drug Designation (US)
|
Phase
III
FJORD
|
BP
|
Placebo
or Fasenra 30mg Q4W
SC
|
Proportion
of patients with partial or
complete
remission of BP whilst off OCS for ≥2 months
at Week
36
|
Data
anticipated 2021+
|
Initiating
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
AZD1222
|
||||
Phase
I/II
COV00163
(UK)
|
Protection
against COVID-19 in participants aged 18-55
|
Control
or
AZD1222
n=1,077
|
FPCD
Q2
2020
LPCD
Q2
2020
|
Initial
data read out
|
Phase
II/III
COV00269
(UK)
|
Protection
against COVID-19 in participants aged 18-55, 55+ and
paediatric
|
Control
or
AZD1222
n=10,260
|
FPCD
Q2
2020
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
Phase
III
D8110C00001
(US)
|
Protection
against COVID-19 in participants aged 18+
|
Placebo
or AZD1222
n=30,000
|
First
data anticipated
H2
2020
|
Initiating
|
Phase
I/IIChAdOx1 nCoV-19 ZA64
(South
Africa)
|
Protection
against COVID-19 in participants aged 18-65
HIV+65
subgroup
|
Placebo
or AZD1222
n=2,200
|
FPCD
Q2
2020
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
Phase
II/III
COV00366
(Brazil)
|
Protection
against COVID-19 in participants aged 18-55
|
Control
or
AZD1222
n>=5,000
|
FPCD
Q2
2020
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
AZD7442
|
||||
Phase
I
|
COVID-19
|
Placebo
or AZD7442
|
-
|
Initiating
|
Calquence
|
||||
Phase
II
CALAVI
(US and
ex-US)
|
COVID-19
|
Current
SoC or SoC+ Calquence
|
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
Phase
II
ACCORD67
|
COVID-19
|
Current
SoC or current SoC + Calquence
|
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
Farxiga
|
||||
Phase
II
DARE-19
|
COVID-19
|
Current
SoC or current SoC +
Farxiga
|
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
Phase
II
TACTIC-E68
|
COVID-19
|
Current
SoC or current SoC + Farxiga + ambrisentan
|
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
MEDI3506
|
||||
Phase
II
ACCORD69
|
COVID-19
|
Current
SoC or current SoC + MEDI3506
|
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
Pulmicort
|
||||
Phase
IIIa
TACTIC-COVID70
|
COVID-19
|
Current
SoC or SoC + Pulmicort
|
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
Phase
IIIa
STOIC71
|
COVID-19
|
Current
SoC or SoC + Pulmicort
|
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
Symbicort
|
||||
Phase
IIIa
INHASCO72
|
COVID-19
|
Current
SoC or SoC + Symbicort
|
First
data anticipated
H2
2020
|
Recruitment
ongoing
|
For the half
year ended 30
June
|
2020
|
2019
|
$m
|
$m
|
|
Total Revenue
|
12,629
|
11,314
|
Product Sales
|
12,359
|
11,183
|
Collaboration Revenue
|
270
|
131
|
|
|
|
Cost of Sales
|
(2,404)
|
(2,192)
|
|
|
|
Gross Profit
|
10,225
|
9,122
|
|
|
|
Distribution costs
|
(191)
|
(159)
|
Research and development expense
|
(2,777)
|
(2,622)
|
Selling, general and administrative costs
|
(5,354)
|
(5,457)
|
Other operating income and expense
|
601
|
706
|
|
|
|
Operating Profit
|
2,504
|
1,590
|
Finance income
|
73
|
96
|
Finance expense
|
(661)
|
(728)
|
Share of after-tax losses in associates and joint
ventures
|
(20)
|
(59)
|
|
|
|
Profit Before Tax
|
1,896
|
899
|
Taxation
|
(408)
|
(229)
|
Profit for the period
|
1,488
|
670
|
|
|
|
Other comprehensive income
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
Remeasurement of the defined benefit pension liability
|
(205)
|
(247)
|
Net gains/(losses) on equity investments measured at fair value
through other comprehensive income
|
1,069
|
(54)
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
6
|
(2)
|
Tax on items that will not be reclassified to profit or
loss
|
(79)
|
17
|
|
791
|
(286)
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
Foreign exchange arising on consolidation
|
(494)
|
(86)
|
Foreign exchange arising on designating borrowings in net
investment hedges
|
(17)
|
(186)
|
Fair value movements on cash flow hedges
|
(131)
|
(43)
|
Fair value movements on cash flow hedges transferred to profit or
loss
|
(1)
|
14
|
Fair value movements on derivatives designated in net investment
hedges
|
60
|
(9)
|
Costs of hedging
|
4
|
3
|
Tax on items that may be reclassified subsequently to profit or
loss
|
29
|
20
|
|
(550)
|
(287)
|
Other comprehensive income/(loss) for the period, net of
tax
|
241
|
(573)
|
Total comprehensive income for the period
|
1,729
|
97
|
|
|
|
Profit attributable to:
|
|
|
Owners of the Parent
|
1,536
|
723
|
Non-controlling interests
|
(48)
|
(53)
|
|
1,488
|
670
|
Total comprehensive income attributable to:
|
|
|
Owners of the Parent
|
1,777
|
150
|
Non-controlling interests
|
(48)
|
(53)
|
|
1,729
|
97
|
Basic earnings per $0.25 Ordinary Share
|
$1.17
|
$0.56
|
Diluted earnings per $0.25 Ordinary Share
|
$1.17
|
$0.56
|
|
|
|
Weighted average number of Ordinary Shares in issue
(millions)
|
1,312
|
1,289
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
1,313
|
1,290
|
For the quarter ended 30 June
|
Unreviewed732020
|
Unreviewed2019
|
$m
|
$m
|
|
Total Revenue
|
6,275
|
5,823
|
Product Sales
|
6,048
|
5,718
|
Collaboration Revenue
|
227
|
105
|
Cost of Sales
|
(984)
|
(1,063)
|
Gross Profit
|
5,291
|
4,760
|
|
|
|
Distribution costs
|
(104)
|
(81)
|
Research and development expense
|
(1,389)
|
(1,356)
|
Selling, general and administrative costs
|
(2,635)
|
(2,943)
|
Other operating income and expense
|
121
|
113
|
|
|
|
Operating Profit
|
1,284
|
493
|
Finance income
|
22
|
41
|
Finance expense
|
(329)
|
(361)
|
Share of after-tax losses in associates and joint
ventures
|
(16)
|
(32)
|
|
|
|
Profit Before Tax
|
961
|
141
|
Taxation
|
(223)
|
(34)
|
Profit for the period
|
738
|
107
|
|
|
|
Other comprehensive income
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
Remeasurement of the defined benefit pension liability
|
(645)
|
(257)
|
Net gains/(losses) on equity investments measured at fair value
through other comprehensive income
|
898
|
(174)
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
(15)
|
(1)
|
Tax on items that will not be reclassified to profit or
loss
|
(13)
|
60
|
|
225
|
(372)
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
Foreign exchange arising on consolidation
|
114
|
(139)
|
Foreign exchange arising on designating borrowings in net
investment hedges
|
363
|
(6)
|
Fair value movements on cash flow hedges
|
56
|
11
|
Fair value movements on cash flow hedges transferred to profit or
loss
|
(46)
|
(33)
|
Fair value movements on derivatives designated in net investment
hedges
|
-
|
(12)
|
Costs of hedging
|
9
|
9
|
Tax on items that may be reclassified subsequently to profit or
loss
|
(44)
|
(3)
|
|
452
|
(173)
|
Other comprehensive income/(loss) for the period, net of
tax
|
677
|
(545)
|
Total comprehensive income/(loss) for the period
|
1,415
|
(438)
|
|
|
|
Profit attributable to:
|
|
|
Owners of the Parent
|
756
|
130
|
Non-controlling interests
|
(18)
|
(23)
|
|
738
|
107
|
Total comprehensive income attributable to:
|
|
|
Owners of the Parent
|
1,432
|
(415)
|
Non-controlling interests
|
(17)
|
(23)
|
|
1,415
|
(438)
|
Basic earnings per $0.25 Ordinary Share
|
$0.58
|
$0.09
|
Diluted earnings per $0.25 Ordinary Share
|
$0.58
|
$0.10
|
|
|
|
Weighted average number of Ordinary Shares in issue
(millions)
|
1,312
|
1,311
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
1,313
|
1,312
|
|
At 30 Jun 2020
|
At 31 Dec 2019
|
At 30 Jun 2019
|
$m
|
$m
|
$m
|
|
Assets
|
|
|
|
Non-current assets
|
|
|
|
Property, plant and equipment
|
7,475
|
7,688
|
7,442
|
Right-of-use assets
|
634
|
647
|
702
|
Goodwill
|
11,645
|
11,668
|
11,668
|
Intangible assets
|
19,728
|
20,833
|
22,257
|
Investments in associates and joint ventures
|
41
|
58
|
73
|
Other investments
|
1,577
|
1,401
|
1,362
|
Derivative financial instruments
|
122
|
61
|
124
|
Other receivables
|
644
|
740
|
454
|
Deferred tax assets
|
3,133
|
2,718
|
2,588
|
|
|
|
|
|
44,999
|
45,814
|
46,670
|
|
|
|
|
Current assets
|
|
|
|
Inventories
|
3,562
|
3,193
|
3,197
|
Trade and other receivables
|
5,024
|
5,761
|
5,319
|
Other investments
|
442
|
849
|
819
|
Derivative financial instruments
|
16
|
36
|
210
|
Income tax receivable
|
213
|
285
|
246
|
Cash and cash equivalents
|
5,673
|
5,369
|
5,428
|
Assets held for sale
|
-
|
70
|
-
|
|
14,930
|
15,563
|
15,219
|
|
|
|
|
Total assets
|
59,929
|
61,377
|
61,889
|
|
|
|
|
|
|
|
|
Liabilities
|
|
|
|
Current liabilities
|
|
|
|
Interest-bearing loans and borrowings
|
(3,958)
|
(1,822)
|
(1,629)
|
Lease liabilities
|
(174)
|
(188)
|
(206)
|
Trade and other payables
|
(12,028)
|
(13,987)
|
(12,637)
|
Derivative financial instruments
|
(35)
|
(36)
|
(11)
|
Provisions
|
(612)
|
(723)
|
(410)
|
Income tax payable
|
(1,376)
|
(1,361)
|
(1,141)
|
|
(18,183)
|
(18,117)
|
(16,034)
|
Non-current liabilities
|
|
|
|
Interest-bearing loans and borrowings
|
(15,150)
|
(15,730)
|
(17,355)
|
Lease liabilities
|
(465)
|
(487)
|
(514)
|
Derivative financial instruments
|
(121)
|
(18)
|
(2)
|
Deferred tax liabilities
|
(2,526)
|
(2,490)
|
(2,932)
|
Retirement benefit obligations
|
(2,847)
|
(2,807)
|
(2,632)
|
Provisions
|
(835)
|
(841)
|
(376)
|
Other payables
|
(6,144)
|
(6,291)
|
(6,973)
|
|
(28,088)
|
(28,664)
|
(30,784)
|
Total liabilities
|
(46,271)
|
(46,781)
|
(46,818)
|
|
|
|
|
Net assets
|
13,658
|
14,596
|
15,071
|
|
|
|
|
Equity
|
|
|
|
Capital and reserves attributable to equity holders of the
Parent
|
|
|
|
Share capital
|
328
|
328
|
328
|
Share premium account
|
7,950
|
7,941
|
7,911
|
Other reserves
|
2,046
|
2,046
|
2,044
|
Retained earnings
|
1,913
|
2,812
|
3,265
|
|
|
|
|
|
12,237
|
13,127
|
13,548
|
|
|
|
|
Non-controlling interests
|
1,421
|
1,469
|
1,523
|
Total equity
|
13,658
|
14,596
|
15,071
|
|
Share capital
|
Share premium account
|
Other reserves
|
Retained earnings
|
Total attributable to owners of the parent
|
Non-controlling interests
|
Total equity
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
At 1 Jan 2019
|
317
|
4,427
|
2,041
|
5,683
|
12,468
|
1,576
|
14,044
|
|
|
|
|
|
|
|
|
Adoption of new accounting standards
|
-
|
-
|
-
|
54
|
54
|
-
|
54
|
Profit for the period
|
-
|
-
|
-
|
723
|
723
|
(53)
|
670
|
Other comprehensive loss
|
-
|
-
|
-
|
(573)
|
(573)
|
-
|
(573)
|
Transfer to other reserves
|
-
|
-
|
3
|
(3)
|
-
|
-
|
-
|
Transactions with owners:
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(2,403)
|
(2,403)
|
-
|
(2,403)
|
Issue of Ordinary Shares
|
11
|
3,484
|
-
|
-
|
3,495
|
-
|
3,495
|
Share-based payments charge for the period
|
-
|
-
|
-
|
102
|
102
|
-
|
102
|
Settlement of share plan awards
|
-
|
-
|
-
|
(318)
|
(318)
|
-
|
(318)
|
|
|
|
|
|
|
|
|
Net movement
|
11
|
3,484
|
3
|
(2,418)
|
1,080
|
(53)
|
1,027
|
|
|
|
|
|
|
|
|
At 30 Jun 2019
|
328
|
7,911
|
2,044
|
3,265
|
13,548
|
1,523
|
15,071
|
|
|
|
|
|
|
|
|
At 1 Jan 2020
|
328
|
7,941
|
2,046
|
2,812
|
13,127
|
1,469
|
14,596
|
|
|
|
|
|
|
|
|
Profit for the period
|
-
|
-
|
-
|
1,536
|
1,536
|
(48)
|
1,488
|
Other comprehensive income
|
-
|
-
|
-
|
241
|
241
|
-
|
241
|
Transfer to other reserves
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Transactions with owners:
|
|
|
|
|
|
|
-
|
Dividends
|
-
|
-
|
-
|
(2,489)
|
(2,489)
|
-
|
(2,489)
|
Issue of Ordinary Shares
|
-
|
9
|
-
|
-
|
9
|
-
|
9
|
Share-based payments charge for the period
|
-
|
-
|
-
|
118
|
118
|
-
|
118
|
Settlement of share plan awards
|
-
|
-
|
-
|
(305)
|
(305)
|
-
|
(305)
|
|
|
|
|
|
|
|
|
Net movement
|
-
|
9
|
-
|
(899)
|
(890)
|
(48)
|
(938)
|
|
|
|
|
|
|
|
|
At 30 Jun 2020
|
328
|
7,950
|
2,046
|
1,913
|
12,237
|
1,421
|
13,658
|
For the half year ended 30 June
|
2020
|
2019
|
$m
|
$m
|
|
Cash flows from operating activities
|
|
|
Profit Before Tax
|
1,896
|
899
|
Finance income and expense
|
588
|
632
|
Share of after-tax losses of associates and joint
ventures
|
20
|
59
|
Depreciation, amortisation and impairment
|
1,551
|
1,403
|
Increase in working capital and short-term provisions
|
(780)
|
(634)
|
Gains on disposal of intangible assets
|
(411)
|
(590)
|
Fair value movements on contingent consideration arising from
business combinations
|
(44)
|
-
|
Non-cash and other movements
|
(511)
|
(177)
|
|
|
|
Cash generated from operations
|
2,309
|
1,592
|
Interest paid
|
(338)
|
(378)
|
Tax paid
|
(792)
|
(723)
|
|
|
|
Net cash inflow from operating activities
|
1,179
|
491
|
|
|
|
Cash flows from investing activities
|
|
|
Payment of contingent consideration from business
combinations
|
(353)
|
(368)
|
Purchase of property, plant and equipment
|
(370)
|
(438)
|
Disposal of property, plant and equipment
|
67
|
27
|
Purchase of intangible assets
|
(983)
|
(1,296)
|
Disposal of intangible assets
|
474
|
1,071
|
Movement
in profit-participation liability
|
-
|
150
|
Purchase of non-current asset investments
|
(119)
|
(7)
|
Disposal of non-current asset investments
|
949
|
18
|
Movement in short-term investments, fixed deposits and other
investing instruments
|
463
|
21
|
Payments to associates and joint ventures
|
(8)
|
(39)
|
Interest received
|
37
|
72
|
|
|
|
Net cash inflow/(outflow) from investing activities
|
157
|
(789)
|
|
|
|
Net cash inflow/(outflow) before financing activities
|
1,336
|
(298)
|
|
|
|
Cash flows from financing activities
|
|
|
Proceeds from issue of share capital
|
9
|
3,495
|
Issue of loans
|
-
|
500
|
Repayment of loans
|
-
|
(500)
|
Dividends paid
|
(2,398)
|
(2,432)
|
Hedge contracts relating to dividend payments
|
(93)
|
26
|
Repayment of obligations under leases
|
(107)
|
(84)
|
Movement in short-term borrowings
|
1,353
|
(64)
|
|
|
|
Net cash (outflow)/inflow from financing activities
|
(1,236)
|
941
|
|
|
|
Net increase in cash and cash equivalents in the
period
|
100
|
643
|
Cash and cash equivalents at the beginning of the
period
|
5,223
|
4,671
|
Exchange rate effects
|
(18)
|
16
|
|
|
|
Cash and cash equivalents at the end of the period
|
5,305
|
5,330
|
|
|
|
Cash and cash equivalents consist of:
|
|
|
Cash and cash equivalents
|
5,673
|
5,428
|
Overdrafts
|
(368)
|
(98)
|
|
|
|
|
5,305
|
5,330
|
|
At
1 Jan 2020
|
Cash flow
|
Non-cash & other
|
Exchange movements
|
At
30 Jun 2020
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
Non-current instalments of loans
|
(15,730)
|
-
|
550
|
30
|
(15,150)
|
Non-current instalments of leases
|
(487)
|
-
|
11
|
11
|
(465)
|
|
|
|
|
|
|
Total long-term debt
|
(16,217)
|
-
|
561
|
41
|
(15,615)
|
|
|
|
|
|
|
Current instalments of loans
|
(1,597)
|
-
|
(556)
|
(6)
|
(2,159)
|
Current instalments of leases
|
(188)
|
117
|
(107)
|
4
|
(174)
|
Commercial paper
|
-
|
(1,262)
|
-
|
-
|
(1,262)
|
Bank collateral
|
(71)
|
(34)
|
-
|
-
|
(105)
|
Other short-term borrowings excluding overdrafts
|
(8)
|
(57)
|
-
|
1
|
(64)
|
Overdraft
|
(146)
|
(230)
|
-
|
8
|
(368)
|
|
|
|
|
|
|
Total current debt
|
(2,010)
|
(1,466)
|
(663)
|
7
|
(4,132)
|
|
|
|
|
|
|
Gross borrowings
|
(18,227)
|
(1,466)
|
(102)
|
48
|
(19,747)
|
|
|
|
|
|
|
Net derivative financial instruments
|
43
|
93
|
(154)
|
-
|
(18)
|
|
|
|
|
|
|
Net borrowings
|
(18,184)
|
(1,373)
|
(256)
|
48
|
(19,765)
|
|
|
|
|
|
|
Cash and cash equivalents
|
5,369
|
330
|
-
|
(26)
|
5,673
|
Other investments - current
|
849
|
(463)
|
62
|
(6)
|
442
|
Other investments - non-current
|
62
|
-
|
(62)
|
-
|
-
|
Cash and investments
|
6,280
|
(133)
|
-
|
(32)
|
6,115
|
|
|
|
|
|
|
Net Debt
|
(11,904)
|
(1,506)
|
(256)
|
16
|
(13,650)
|
|
2020
|
2019
|
||
Diabetes alliance
|
Other
|
Total
|
Total
|
|
$m
|
$m
|
$m
|
$m
|
|
At 1 January
|
3,300
|
839
|
4,139
|
5,106
|
Settlements
|
(257)
|
(96)
|
(353)
|
(368)
|
Revaluations
|
(22)
|
(22)
|
(44)
|
-
|
Discount unwind
|
115
|
26
|
141
|
179
|
|
|
|
|
|
At 30 June
|
3,136
|
747
|
3,883
|
4,917
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
|||||
Actual
|
CER
|
Actual
|
CER
|
Actual
|
Actual
|
CER
|
Actual
|
CER
|
||||||
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
2,016
|
43
|
45
|
595
|
81
|
89
|
725
|
30
|
325
|
53
|
58
|
371
|
18
|
18
|
Imfinzi
|
954
|
51
|
52
|
63
|
n/m
|
n/m
|
574
|
21
|
167
|
n/m
|
n/m
|
150
|
70
|
71
|
Lynparza
|
816
|
57
|
60
|
120
|
n/m
|
n/m
|
406
|
55
|
198
|
51
|
56
|
92
|
35
|
34
|
Calquence
|
195
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
193
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
Koselugo
|
7
|
n/m
|
n/m
|
-
|
-
|
-
|
7
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
Zoladex*
|
442
|
13
|
18
|
288
|
22
|
29
|
5
|
40
|
68
|
5
|
8
|
81
|
(7)
|
(6)
|
Faslodex*
|
312
|
(40)
|
(38)
|
100
|
4
|
10
|
34
|
(87)
|
116
|
6
|
9
|
62
|
(4)
|
(4)
|
Iressa*
|
147
|
(42)
|
(40)
|
120
|
(27)
|
(24)
|
7
|
(3)
|
9
|
(81)
|
(81)
|
11
|
(67)
|
(66)
|
Arimidex*
|
107
|
(3)
|
-
|
90
|
26
|
30
|
-
|
-
|
1
|
(90)
|
(90)
|
16
|
(32)
|
(32)
|
Casodex*
|
89
|
(15)
|
(13)
|
69
|
8
|
11
|
-
|
-
|
1
|
(84)
|
(84)
|
19
|
(43)
|
(42)
|
Others
|
26
|
(50)
|
(47)
|
14
|
(23)
|
(14)
|
-
|
-
|
3
|
(15)
|
(16)
|
9
|
(64)
|
(69)
|
Total Oncology
|
5,111
|
26
|
28
|
1,461
|
39
|
46
|
1,951
|
20
|
888
|
37
|
41
|
811
|
10
|
9
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
848
|
17
|
21
|
306
|
49
|
59
|
237
|
(12)
|
223
|
25
|
29
|
82
|
14
|
15
|
Brilinta
|
845
|
15
|
17
|
291
|
34
|
40
|
351
|
9
|
173
|
2
|
5
|
30
|
7
|
10
|
Onglyza
|
256
|
(5)
|
(3)
|
100
|
15
|
21
|
105
|
(12)
|
29
|
(21)
|
(18)
|
22
|
(15)
|
(13)
|
Bydureon
|
216
|
(24)
|
(23)
|
2
|
(74)
|
(72)
|
185
|
(21)
|
24
|
(29)
|
(26)
|
5
|
(37)
|
(34)
|
Byetta
|
35
|
(36)
|
(35)
|
5
|
13
|
21
|
19
|
(47)
|
7
|
(29)
|
(26)
|
4
|
(21)
|
(20)
|
Other diabetes
|
23
|
3
|
6
|
3
|
n/m
|
n/m
|
13
|
(21)
|
6
|
44
|
50
|
1
|
(60)
|
(25)
|
Lokelma
|
28
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
22
|
n/m
|
2
|
n/m
|
n/m
|
3
|
n/m
|
n/m
|
Crestor*
|
582
|
(10)
|
(8)
|
369
|
(9)
|
(6)
|
45
|
(17)
|
64
|
(15)
|
(13)
|
104
|
(5)
|
(5)
|
Seloken/Toprol-XL*
|
395
|
-
|
6
|
376
|
8
|
14
|
6
|
(78)
|
8
|
(39)
|
(39)
|
5
|
-
|
5
|
Atacand*
|
126
|
19
|
25
|
94
|
23
|
31
|
5
|
(15)
|
15
|
(2)
|
(2)
|
12
|
37
|
43
|
Others
|
106
|
(20)
|
(18)
|
65
|
(30)
|
(28)
|
-
|
-
|
35
|
15
|
18
|
6
|
(36)
|
(39)
|
BioPharmaceuticals: total CVRM
|
3,460
|
3
|
6
|
1,612
|
11
|
17
|
988
|
(9)
|
586
|
3
|
6
|
274
|
-
|
2
|
BioPharmaceuticals: Respiratory & Immunology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
1,442
|
23
|
26
|
290
|
10
|
16
|
558
|
46
|
356
|
1
|
4
|
238
|
39
|
42
|
Pulmicort
|
477
|
(33)
|
(32)
|
371
|
(36)
|
(34)
|
36
|
(36)
|
40
|
(8)
|
(4)
|
30
|
(26)
|
(25)
|
Fasenra
|
426
|
44
|
45
|
7
|
n/m
|
n/m
|
272
|
31
|
88
|
96
|
n/m
|
59
|
41
|
41
|
Daliresp/Daxas
|
106
|
1
|
2
|
2
|
(13)
|
(7)
|
90
|
1
|
13
|
7
|
11
|
1
|
(3)
|
(36)
|
Bevespi
|
22
|
10
|
10
|
-
|
-
|
-
|
21
|
5
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
Breztri
|
11
|
n/m
|
n/m
|
9
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
2
|
n/m
|
n/m
|
Others
|
184
|
(20)
|
(18)
|
80
|
(29)
|
(27)
|
7
|
n/m
|
89
|
(16)
|
(14)
|
8
|
(14)
|
4
|
BioPharmaceuticals: total Respiratory & Immunology
|
2,668
|
5
|
7
|
759
|
(21)
|
(18)
|
984
|
30
|
587
|
5
|
8
|
338
|
29
|
31
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
714
|
(5)
|
(3)
|
371
|
-
|
5
|
80
|
(32)
|
36
|
14
|
18
|
227
|
(4)
|
(4)
|
Synagis
|
176
|
18
|
18
|
5
|
n/m
|
n/m
|
21
|
(40)
|
150
|
32
|
32
|
-
|
-
|
-
|
Losec/Prilosec
|
99
|
(32)
|
(30)
|
81
|
(15)
|
(12)
|
3
|
(44)
|
10
|
(68)
|
(68)
|
5
|
(62)
|
(62)
|
Seroquel XR/IR
|
63
|
(9)
|
(8)
|
27
|
11
|
15
|
14
|
n/m
|
15
|
(69)
|
(69)
|
7
|
(36)
|
(37)
|
Others
|
68
|
(32)
|
(31)
|
3
|
(64)
|
(73)
|
33
|
(44)
|
28
|
5
|
5
|
4
|
(34)
|
(22)
|
Total other medicines
|
1,120
|
(8)
|
(6)
|
487
|
(2)
|
1
|
151
|
(26)
|
239
|
(4)
|
(4)
|
243
|
(9)
|
(9)
|
Total Product Sales
|
12,359
|
11
|
13
|
4,319
|
9
|
14
|
4,074
|
11
|
2,300
|
13
|
17
|
1,666
|
8
|
9
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
|||||
Actual
|
CER
|
Actual
|
CER
|
Actual
|
Actual
|
CER
|
Actual
|
CER
|
||||||
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
1,034
|
32
|
35
|
315
|
65
|
74
|
354
|
18
|
163
|
46
|
51
|
202
|
12
|
12
|
Imfinzi
|
492
|
46
|
48
|
30
|
n/m
|
n/m
|
287
|
19
|
93
|
n/m
|
n/m
|
82
|
55
|
56
|
Lynparza
|
419
|
48
|
52
|
64
|
95
|
n/m
|
209
|
47
|
96
|
45
|
50
|
50
|
20
|
21
|
Calquence
|
107
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
107
|
n/m
|
-
|
-
|
-
|
(1)
|
n/m
|
n/m
|
Koselugo
|
7
|
n/m
|
n/m
|
-
|
-
|
-
|
7
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
Zoladex*
|
217
|
10
|
17
|
139
|
15
|
24
|
3
|
55
|
33
|
8
|
14
|
42
|
(4)
|
(2)
|
Faslodex*
|
146
|
(45)
|
(43)
|
52
|
2
|
10
|
11
|
(91)
|
52
|
(7)
|
(3)
|
31
|
(13)
|
(13)
|
Iressa*
|
70
|
(41)
|
(38)
|
58
|
(26)
|
(23)
|
4
|
(5)
|
3
|
(85)
|
(85)
|
5
|
(65)
|
(62)
|
Arimidex*
|
58
|
(4)
|
-
|
48
|
35
|
41
|
-
|
-
|
1
|
(93)
|
(93)
|
9
|
(42)
|
(43)
|
Casodex*
|
47
|
(17)
|
(15)
|
37
|
8
|
11
|
-
|
-
|
-
|
n/m
|
n/m
|
10
|
(47)
|
(46)
|
Others
|
12
|
(59)
|
(55)
|
6
|
(35)
|
(18)
|
(1)
|
n/m
|
1
|
(32)
|
(35)
|
6
|
(67)
|
(74)
|
Total Oncology
|
2,609
|
20
|
24
|
750
|
34
|
43
|
981
|
15
|
442
|
32
|
37
|
436
|
3
|
4
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
443
|
17
|
23
|
165
|
49
|
62
|
124
|
(11)
|
107
|
20
|
25
|
47
|
24
|
26
|
Brilinta
|
437
|
12
|
16
|
156
|
30
|
39
|
187
|
11
|
80
|
(9)
|
(5)
|
14
|
6
|
10
|
Bydureon
|
116
|
(18)
|
(17)
|
1
|
(87)
|
(86)
|
101
|
(14)
|
12
|
(22)
|
(19)
|
2
|
(23)
|
(18)
|
Onglyza
|
115
|
(1)
|
3
|
52
|
19
|
27
|
38
|
(9)
|
14
|
(22)
|
(19)
|
11
|
(20)
|
(17)
|
Byetta
|
15
|
(42)
|
(41)
|
2
|
(37)
|
(30)
|
7
|
(53)
|
4
|
(16)
|
(13)
|
2
|
(26)
|
(26)
|
Other diabetes
|
10
|
(9)
|
(5)
|
1
|
n/m
|
n/m
|
6
|
(31)
|
3
|
37
|
44
|
-
|
n/m
|
n/m
|
Lokelma
|
17
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
12
|
n/m
|
1
|
n/m
|
n/m
|
3
|
n/m
|
n/m
|
Crestor*
|
281
|
(10)
|
(6)
|
177
|
(3)
|
2
|
17
|
(40)
|
30
|
(18)
|
(16)
|
57
|
(11)
|
(10)
|
Seloken/Toprol-XL*
|
218
|
29
|
38
|
210
|
35
|
45
|
2
|
(53)
|
4
|
(48)
|
(48)
|
2
|
2
|
9
|
Atacand*
|
59
|
6
|
14
|
45
|
21
|
33
|
2
|
(39)
|
6
|
(43)
|
(43)
|
6
|
43
|
52
|
Others
|
48
|
(23)
|
(20)
|
29
|
(31)
|
(28)
|
-
|
-
|
16
|
25
|
29
|
3
|
(65)
|
(69)
|
BioPharmaceuticals: total CVRM
|
1,759
|
6
|
10
|
839
|
20
|
28
|
496
|
(6)
|
277
|
(3)
|
1
|
147
|
(1)
|
1
|
BioPharmaceuticals: Respiratory & Immunology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
653
|
12
|
15
|
135
|
3
|
12
|
248
|
20
|
161
|
(6)
|
(3)
|
109
|
42
|
47
|
Pulmicort
|
97
|
(71)
|
(69)
|
58
|
(78)
|
(76)
|
13
|
(60)
|
15
|
(21)
|
(18)
|
11
|
(43)
|
(42)
|
Fasenra
|
227
|
36
|
37
|
1
|
(30)
|
(5)
|
152
|
33
|
42
|
57
|
63
|
32
|
32
|
33
|
Daliresp/Daxas
|
53
|
(7)
|
(7)
|
1
|
(17)
|
(9)
|
45
|
(7)
|
6
|
(3)
|
1
|
1
|
(37)
|
(70)
|
Bevespi
|
10
|
(1)
|
(3)
|
-
|
-
|
-
|
9
|
(6)
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
Breztri
|
7
|
n/m
|
n/m
|
5
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
2
|
n/m
|
n/m
|
Others
|
70
|
(30)
|
(28)
|
21
|
(52)
|
(52)
|
5
|
n/m
|
42
|
(18)
|
(15)
|
2
|
(60)
|
(36)
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,117
|
(11)
|
(8)
|
221
|
(50)
|
(46)
|
472
|
15
|
267
|
(3)
|
1
|
157
|
23
|
26
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
377
|
(4)
|
(1)
|
184
|
3
|
9
|
40
|
(24)
|
15
|
(7)
|
(4)
|
138
|
(5)
|
(5)
|
Synagis
|
90
|
(5)
|
(5)
|
-
|
-
|
-
|
14
|
41
|
76
|
(11)
|
(11)
|
-
|
-
|
-
|
Losec/Prilosec
|
45
|
(34)
|
(31)
|
37
|
(16)
|
(12)
|
1
|
(90)
|
5
|
(60)
|
(60)
|
2
|
(75)
|
(74)
|
Seroquel XR/IR
|
27
|
(16)
|
(14)
|
15
|
49
|
57
|
1
|
n/m
|
7
|
(71)
|
(71)
|
4
|
(23)
|
(25)
|
Others
|
24
|
(53)
|
(52)
|
2
|
(88)
|
(93)
|
8
|
(74)
|
13
|
3
|
1
|
1
|
n/m
|
n/m
|
Total other medicines
|
563
|
(12)
|
(10)
|
238
|
(5)
|
-
|
64
|
(29)
|
116
|
(23)
|
(23)
|
145
|
(3)
|
(3)
|
Total Product Sales
|
6,048
|
6
|
9
|
2,048
|
5
|
12
|
2,013
|
7
|
1,102
|
5
|
9
|
885
|
4
|
5
|
|
Q1 2020
|
Q2 2020
|
||||
$m
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||
Oncology
|
|
|
|
|
|
|
Tagrisso
|
982
|
11
|
11
|
1,034
|
5
|
7
|
Imfinzi
|
462
|
9
|
9
|
492
|
6
|
8
|
Lynparza
|
397
|
13
|
13
|
419
|
5
|
7
|
Calquence
|
88
|
58
|
58
|
107
|
21
|
23
|
Koselugo
|
-
|
-
|
-
|
7
|
n/m
|
n/m
|
Zoladex*
|
225
|
15
|
15
|
217
|
(3)
|
-
|
Faslodex*
|
166
|
-
|
-
|
146
|
(12)
|
(9)
|
Iressa*
|
77
|
(3)
|
(4)
|
70
|
(9)
|
(7)
|
Arimidex*
|
50
|
(1)
|
(2)
|
58
|
17
|
16
|
Casodex*
|
42
|
(2)
|
(3)
|
47
|
14
|
12
|
Others
|
13
|
(52)
|
(52)
|
12
|
(11)
|
(1)
|
Total Oncology
|
2,502
|
10
|
10
|
2,609
|
4
|
6
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
Farxiga
|
405
|
(3)
|
(3)
|
443
|
9
|
13
|
Brilinta
|
408
|
(5)
|
(5)
|
437
|
7
|
9
|
Onglyza
|
141
|
8
|
8
|
115
|
(19)
|
(17)
|
Bydureon
|
100
|
(28)
|
(28)
|
116
|
16
|
17
|
Byetta
|
20
|
(24)
|
(24)
|
15
|
(28)
|
(28)
|
Other diabetes
|
13
|
(22)
|
(22)
|
10
|
(21)
|
(19)
|
Lokelma
|
11
|
42
|
42
|
17
|
56
|
58
|
Crestor*
|
301
|
2
|
1
|
281
|
(7)
|
(4)
|
Seloken/Toprol-XL*
|
177
|
(6)
|
(6)
|
218
|
23
|
27
|
Atacand*
|
66
|
11
|
12
|
59
|
(11)
|
(5)
|
Others
|
59
|
(21)
|
(22)
|
48
|
(18)
|
(16)
|
BioPharmaceuticals: total CVRM
|
1,701
|
(5)
|
(5)
|
1,759
|
3
|
6
|
BioPharmaceuticals: Respiratory & Immunology
|
|
|
|
|
|
|
Symbicort
|
790
|
11
|
11
|
653
|
(17)
|
(15)
|
Pulmicort
|
380
|
(8)
|
(9)
|
97
|
(74)
|
(73)
|
Fasenra
|
199
|
(3)
|
(3)
|
227
|
14
|
15
|
Daliresp/Daxas
|
53
|
(8)
|
(8)
|
53
|
(1)
|
(3)
|
Bevespi
|
12
|
9
|
9
|
10
|
(19)
|
(21)
|
Breztri
|
4
|
n/m
|
n/m
|
7
|
58
|
64
|
Others
|
113
|
(16)
|
(17)
|
70
|
(38)
|
(36)
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,551
|
1
|
1
|
1,117
|
(28)
|
(26)
|
Other medicines
|
|
|
|
|
|
|
Nexium
|
338
|
(4)
|
(4)
|
377
|
12
|
14
|
Synagis
|
85
|
35
|
35
|
90
|
6
|
7
|
Losec/Prilosec
|
54
|
18
|
17
|
45
|
(15)
|
(15)
|
Seroquel XR/IR
|
36
|
(12)
|
(12)
|
27
|
(26)
|
(23)
|
Others
|
44
|
(71)
|
(70)
|
24
|
(46)
|
(42)
|
Total other medicines
|
557
|
(15)
|
(15)
|
563
|
1
|
4
|
Total Product Sales
|
6,311
|
1
|
1
|
6,048
|
(4)
|
(2)
|
|
Q1 2019
|
Q2 2019
|
Q3 2019
|
Q4 2019
|
||||||||
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
|||||
Actual
|
CER
|
Actual
|
CER
|
Actual
|
CER
|
Actual
|
CER
|
|||||
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
630
|
6
|
6
|
784
|
24
|
25
|
891
|
14
|
13
|
884
|
(1)
|
-
|
Imfinzi
|
295
|
13
|
13
|
338
|
15
|
15
|
412
|
22
|
22
|
424
|
3
|
4
|
Lynparza
|
237
|
13
|
13
|
283
|
19
|
20
|
327
|
16
|
15
|
351
|
7
|
8
|
Calquence
|
29
|
21
|
23
|
35
|
21
|
19
|
44
|
27
|
27
|
56
|
25
|
25
|
Faslodex*
|
254
|
(6)
|
(6)
|
267
|
5
|
6
|
205
|
(23)
|
(23)
|
166
|
(20)
|
(19)
|
Zoladex*
|
194
|
7
|
6
|
197
|
2
|
1
|
226
|
15
|
16
|
196
|
(14)
|
(12)
|
Iressa*
|
134
|
20
|
18
|
118
|
(12)
|
(11)
|
91
|
(23)
|
(22)
|
80
|
(13)
|
(12)
|
Arimidex*
|
51
|
11
|
10
|
60
|
18
|
17
|
63
|
5
|
5
|
51
|
(20)
|
(18)
|
Casodex*
|
48
|
4
|
3
|
57
|
19
|
18
|
52
|
(8)
|
(6)
|
43
|
(18)
|
(17)
|
Others
|
20
|
(13)
|
(14)
|
28
|
40
|
29
|
20
|
(27)
|
(22)
|
26
|
30
|
26
|
Total Oncology
|
1,892
|
7
|
6
|
2,167
|
15
|
15
|
2,334
|
8
|
8
|
2,274
|
(3)
|
(2)
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
349
|
(12)
|
(12)
|
377
|
8
|
9
|
398
|
5
|
5
|
419
|
5
|
6
|
Brilinta
|
348
|
(7)
|
(8)
|
389
|
12
|
12
|
416
|
7
|
8
|
428
|
3
|
3
|
Onglyza
|
153
|
3
|
3
|
116
|
(24)
|
(24)
|
127
|
9
|
11
|
131
|
3
|
4
|
Bydureon
|
142
|
3
|
3
|
141
|
(1)
|
-
|
127
|
(10)
|
(10)
|
139
|
9
|
10
|
Byetta
|
30
|
(6)
|
(5)
|
25
|
(17)
|
(16)
|
28
|
10
|
13
|
27
|
(2)
|
(4)
|
Other diabetes
|
11
|
(8)
|
(17)
|
11
|
-
|
8
|
14
|
26
|
22
|
16
|
17
|
17
|
Lokelma
|
-
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
4
|
n/m
|
n/m
|
8
|
87
|
74
|
Crestor*
|
335
|
(5)
|
(6)
|
310
|
(7)
|
(7)
|
337
|
9
|
9
|
296
|
(12)
|
(11)
|
Seloken/Toprol-XL*
|
225
|
41
|
38
|
168
|
(25)
|
(25)
|
177
|
6
|
8
|
190
|
7
|
8
|
Atacand*
|
50
|
(14)
|
(15)
|
56
|
12
|
14
|
55
|
(1)
|
(1)
|
60
|
8
|
9
|
Others
|
71
|
(3)
|
(5)
|
63
|
(11)
|
(8)
|
65
|
4
|
2
|
72
|
13
|
16
|
BioPharmaceuticals: total CVRM
|
1,714
|
(2)
|
(3)
|
1,658
|
(3)
|
(3)
|
1,749
|
5
|
6
|
1,785
|
2
|
3
|
BioPharmaceuticals: Respiratory & Immunology
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
585
|
(8)
|
(8)
|
585
|
-
|
1
|
613
|
5
|
4
|
712
|
16
|
17
|
Pulmicort
|
383
|
(2)
|
(2)
|
333
|
(13)
|
(13)
|
337
|
1
|
3
|
413
|
22
|
23
|
Fasenra
|
129
|
3
|
4
|
167
|
29
|
30
|
202
|
21
|
21
|
206
|
2
|
2
|
Daliresp/Daxas
|
48
|
(11)
|
(12)
|
56
|
17
|
18
|
53
|
(6)
|
(7)
|
58
|
10
|
10
|
Bevespi
|
10
|
-
|
(5)
|
10
|
-
|
2
|
10
|
4
|
8
|
12
|
8
|
5
|
Breztri
|
-
|
-
|
-
|
-
|
-
|
-
|
1
|
-
|
-
|
1
|
(74)
|
(73)
|
Others
|
128
|
(14)
|
(12)
|
101
|
(21)
|
(23)
|
102
|
1
|
(1)
|
135
|
33
|
38
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,283
|
(6)
|
(6)
|
1,252
|
(2)
|
(2)
|
1,319
|
5
|
6
|
1,537
|
17
|
17
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
363
|
(7)
|
(8)
|
393
|
8
|
8
|
374
|
(5)
|
(4)
|
353
|
(6)
|
(6)
|
Synagis
|
53
|
(79)
|
(79)
|
96
|
81
|
81
|
146
|
52
|
53
|
63
|
(57)
|
(57)
|
Losec/Prilosec
|
76
|
27
|
26
|
68
|
(11)
|
(10)
|
73
|
8
|
9
|
46
|
(38)
|
(38)
|
Seroquel XR/IR
|
37
|
(34)
|
(33)
|
32
|
(14)
|
(10)
|
82
|
n/m
|
n/m
|
40
|
(50)
|
(49)
|
Others
|
47
|
(65)
|
(64)
|
52
|
11
|
11
|
56
|
8
|
-
|
151
|
n/m
|
n/m
|
Total other medicines
|
576
|
(35)
|
(36)
|
641
|
11
|
12
|
731
|
14
|
14
|
653
|
(11)
|
(10)
|
Total Product Sales
|
5,465
|
(5)
|
(6)
|
5,718
|
5
|
5
|
6,132
|
7
|
8
|
6,250
|
2
|
3
|
|
|
H1 2020
|
H1 2019
|
FY 2019
|
FY 2018
|
$m
|
$m
|
$m
|
$m
|
||
Initial Collaboration Revenue
|
Crestor (Spain)
|
-
|
-
|
-
|
61
|
Ongoing Collaboration Revenue
|
Lynparza: regulatory
milestones
|
135
|
60
|
60
|
140
|
Lynparza: sales
milestones
|
-
|
-
|
450
|
250
|
|
Lynparza/selumetinib: option
payments
|
-
|
-
|
100
|
400
|
|
Crestor (Spain)
|
-
|
-
|
39
|
-
|
|
Enhertu: profit
share
|
36
|
-
|
-
|
-
|
|
Roxadustat: profit share
|
11
|
-
|
-
|
-
|
|
Royalty income
|
34
|
32
|
62
|
49
|
|
|
Other Collaboration Revenue
|
54
|
39
|
108
|
141
|
Total
|
270
|
131
|
819
|
1,041
|
|
H1 2020
|
H1 2019
|
FY 2019
|
FY 2018
|
$m
|
$m
|
$m
|
$m
|
|
Hypertension medicines (ex-US, India and Japan)
|
350
|
-
|
-
|
-
|
Inderal, Tenormin,
Seloken and Omepral (Japan)
|
51
|
-
|
-
|
-
|
Synagis (US)
|
-
|
515
|
515
|
-
|
Losec (ex-China, Japan, US and
Mexico)
|
-
|
-
|
243
|
-
|
Seroquel and
Seroquel XR
(US, Canada, Europe and
Russia)
|
-
|
-
|
213
|
-
|
Arimidex and
Casodex
(various
countries)
|
-
|
-
|
181
|
-
|
Nexium (Europe) and
Vimovo
(ex-US)
|
-
|
-
|
-
|
728
|
Seroquel
|
-
|
-
|
-
|
527
|
Legal settlement
|
-
|
-
|
-
|
346
|
Atacand
|
-
|
-
|
-
|
210
|
Anaesthetics
|
-
|
-
|
-
|
172
|
Alvesco, Omnaris and Zetonna
|
-
|
-
|
-
|
139
|
Other
|
200
|
191
|
389
|
405
|
|
|
|
|
|
Total
|
601
|
706
|
1,541
|
2,527
|
Announcement of
year to date and third quarter
results
5
November 2020
|
||
Announcement of
full year and fourth quarter
results
11
February 2021
|
||
|
||
Future
dividends will normally be paid as follows:
|
||
First
interim:
|
announced
with half-year and second-quarter results and paid in
September
|
|
Second
interim:
|
announced
with full-year and fourth-quarter results and paid in
March
|
|
|
|
|
Registered office
|
Registrar and transfer office
|
Swedish Central Securities Depository
|
US depositary
Deutsche Bank Trust Company Americas
|
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0AA
|
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA
|
Euroclear Sweden AB PO Box 191
SE-101 23 Stockholm
|
American Stock Transfer
6201 15th Avenue
Brooklyn
NY 11219
|
United Kingdom
|
United Kingdom
|
Sweden
|
United States
|
|
|
|
|
+44 (0) 20 3749 5000
|
0800 389 1580
|
+46 (0) 8 402 9000
|
+1 (888) 697 8018
|
|
+44 (0) 121 415 7033
|
|
+1 (718) 921 8137
|
|
|
|
db@astfinancial.com |
|
AstraZeneca
PLC
|
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|